ST Renfu (600079.SH): Rubiprost softgels have obtained US FDA approval number

Zhitongcaijing · 4d ago

Zhitong Finance App News, ST Renfu (600079.SH) announced that its wholly-owned subsidiary Renfuke Pharmaceutical (Wuhan) Co., Ltd. (“Human Fopke”) recently received an approval number from the US Food and Drug Administration (FDA) for rubiprost softgels.

Rubiprost softgels are approved for the treatment of: (1) adult chronic idiopathic constipation (CIC); (2) opioid-induced constipation (OIC) in adult patients with chronic non-cancerous pain, including those with previous cancer or chronic pain associated with cancer treatment, who do not require frequent (e.g., weekly) opioid dose increases; (3) for constipated irritable bowel syndrome (IBS‑C) in women 18 years and older.